|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4532-4539.
Prepublished online as a Blood First Edition Paper on February 24, 2005; DOI 10.1182/blood-2004-06-2387.
 Previous Article | Table of Contents
TRANSPLANTATION
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
Charles Crawley,
Marc Lalancette,
Richard Szydlo,
Maria Gilleece,
Karl Peggs,
Stephen Mackinnon,
Gunnar Juliusson,
Lucia Ahlberg,
Arnon Nagler,
Avichai Shimoni,
Anna Sureda,
Jean-Michel Boiron,
Herman Einsele,
Rajesh Chopra,
Angelo Carella,
Jamie Cavenagh,
Alois Gratwohl,
Frederic Garban,
Axel Zander,
Bo Björkstrand,
Dietger Niederwieser,
Gösta Gahrton,
Jane F. Apperley, for the Chronic Leukaemia Working Party of the EBMT
From Addenbrooke's Hospital, Cambridge, United Kingdom; Centre Hospitalier Universitaire de Québec (CHUQ) L' Hôtel-Dieu, Quebec, Canada; the Imperial College, Hammersmith Hospital, London, United Kingdom; Ysbyty Gwynedd, Bangor, United Kingdom; University College London, London, United Kingdom; the University Hospital, Lund, Sweden; the University Hospital, Linköping, Sweden; the Chaim Sheba Medical Center, Tel-Hashomer, Israel; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Université Bordeaux 2 V Segalen & Etablissement Français du Sang-AL, Bordeaux, France; the Poliklinik II, Wurzburg, Germany: the Christie Hospital, Manchester, United Kingdom; Azienda Ospedaliera San Martino, Genoa, Italy; St Bartholomew's and The Royal London Hospital, London, United Kingdom; the Kantonsspital, Basel, Switzerland; Hopital A. Michallon, Grenoble, France; the University Hospital Eppendorf, Hamburg, Germany; the Karolinska University Hospital, Huddinge, Stockholm, Sweden; and the University of Leipzig, Leipzig, Germany.
We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity conditioning (RIC) regimens from 33 centers within the European Group for Blood and Marrow Transplantation (EBMT). The median age was 52 years and 64% were male. Conditioning regimens were heterogeneous, but most were fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab. Transplantation-related mortality (TRM) at 1 year was 22%. The 3-year overall survival (OS) and progression-free survival (PFS) were 41% and 21%, respectively. Adverse OS was associated with chemoresistant disease (relative risk [RR], 2.9), more than 1 prior transplantation (RR, 2.0), and male patients with female donors (RR, 1.45). Adverse PFS was associated with chemoresistance (RR, 2.4) and alemtuzumab (RR, 1.8). TRM was increased with female-to-male donation (RR, 2.5) and transplantation more than 1 year from diagnosis (RR, 2.3). Grades II to IV acute graft-versus-host disease (aGvHD) occurred in 31%. Chronic GvHD was associated with better OS and PFS and were 84% and 46% for limited, 58% and 30% for extensive, and 29% and 12% in its absence suggesting that a graft-versus-myeloma effect is important. While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. V. Rajkumar
Treatment of Myeloma: Cure vs Control
Mayo Clin. Proc.,
October 1, 2008;
83(10):
1142 - 1145.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Alici, T. Sutlu, B. Bjorkstrand, M. Gilljam, B. Stellan, H. Nahi, H. C. Quezada, G. Gahrton, H.-G. Ljunggren, and M. S. Dilber
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Blood,
March 15, 2008;
111(6):
3155 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gahrton, S. Iacobelli, G. Bandini, B. Bjorkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kroger, A. Schattenberg, et al.
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma
Haematologica,
November 1, 2007;
92(11):
1513 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin,
September 1, 2007;
57(5):
301 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cavo
Nonmyeloablative allotransplantation for myeloma: light and shade
Blood,
April 15, 2007;
109(8):
3134 - 3135.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, S. Iacobelli, B. Bjorkstrand, J. F. Apperley, D. Niederwieser, G. Gahrton, and for the Chronic Leukaemia Working Party of the Eur
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Blood,
April 15, 2007;
109(8):
3588 - 3594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Rizzieri, L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, C. Smith, J. Z. Gong, A. Lagoo, et al.
Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution
J. Clin. Oncol.,
February 20, 2007;
25(6):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Antin
Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2
Hematology,
January 1, 2007;
2007(1):
47 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau
Stem Cell Transplantation in Multiple Myeloma
Hematology,
January 1, 2007;
2007(1):
311 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Singhal and J. Mehta
Multiple Myeloma
Clin. J. Am. Soc. Nephrol.,
November 1, 2006;
1(6):
1322 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al.
Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation
J. Clin. Oncol.,
September 1, 2006;
24(25):
4150 - 4157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, et al.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
Blood,
May 1, 2006;
107(9):
3474 - 3480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al.
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation
Blood,
March 15, 2006;
107(6):
2578 - 2584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Haubitz and D. Peest
Myeloma - new approaches to combined nephrological-haematological management
Nephrol. Dial. Transplant.,
March 1, 2006;
21(3):
582 - 590.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Giralt
Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years?
Hematology,
January 1, 2005;
2005(1):
384 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
